Wells Fargo Starts Protalix BioTherapeutics (PLX) at Outperform; Attractive Platform
Tweet Send to a Friend
Wells Fargo initiates coverage on Protalix BioTherapeutics (NYSE: PLX) with a Outperform. Valuation Range: $12-$14.
Wells analyst says, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells analyst says, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
